Shield Therapeutics reports sharp rise in first-half revenue

(Sharecast News) - Shield Therapeutics reported a sharp rise in first-half revenue on Wednesday, as sales of its oral iron therapy Accrufer accelerated across key markets, leaving the company on track to reach cash flow breakeven by the end of 2025. For the six months ended 30 June, revenue jumped 1.8 times year-on-year to $21.4m, driven by US sales of Accrufer, which rose to $19.2m from $11m, alongside $2.2m in ex-US milestone and royalty income.

Total prescriptions grew to around 84,000, up from 65,200 a year earlier, with the average net selling price increasing to $214 from $158.

The AIM-traded company narrowed its interim loss to $9.5m from $15.5m as rising sales and tighter cost controls offset higher investment in global partnerships and regulatory filings.

Cash and equivalents stood at $10.8m, boosted by $10m in equity funding, increased product revenues, and milestone payments from partners in Japan and Europe.

"We are encouraged by Accrufer's strong performance in the first half of 2025, following the increasing market adoption of Accrufer, which further validates its substantial potential," said chief executive Anders Lundstrom.

"Operationally, we made significant progress globally, including the launch of Accrufer in Canada, a new licensing agreement in Japan, and the successful completion of a key phase three study in China.

"We also submitted regulatory filings for pediatric use in both Europe and the US following positive trial results.

"We remain committed to driving sustained growth and establishing Accrufer as the preferred oral iron therapy for patients with iron deficiency, with or without anemia.

"Our cash position strengthened to $10.8 million, and we remain on track to turn cash flow positive by year-end."

The firm said filings in China, Europe and the US could pave the way for expanded indications from 2026, while international licensing agreements continued to provide additional milestones and royalties.

At 1404 BST, shares in Shield Therapeutics were down 8.63% at 6.35p.

Reporting by Josh White for Sharecast.com.